DE602004010889T2 - Sulfonamid-derivate als ppar-modulatoren - Google Patents
Sulfonamid-derivate als ppar-modulatoren Download PDFInfo
- Publication number
- DE602004010889T2 DE602004010889T2 DE602004010889T DE602004010889T DE602004010889T2 DE 602004010889 T2 DE602004010889 T2 DE 602004010889T2 DE 602004010889 T DE602004010889 T DE 602004010889T DE 602004010889 T DE602004010889 T DE 602004010889T DE 602004010889 T2 DE602004010889 T2 DE 602004010889T2
- Authority
- DE
- Germany
- Prior art keywords
- alkyl
- aryl
- hydrogen
- heteroaryl
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229940124530 sulfonamide Drugs 0.000 title claims 3
- 150000003456 sulfonamides Chemical class 0.000 title claims 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title abstract 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 claims abstract 25
- 150000003839 salts Chemical class 0.000 claims abstract 12
- 239000012453 solvate Substances 0.000 claims abstract 12
- 150000004677 hydrates Chemical class 0.000 claims abstract 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 4
- 208000011580 syndromic disease Diseases 0.000 claims abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract 2
- 206010020772 Hypertension Diseases 0.000 claims abstract 2
- 208000008589 Obesity Diseases 0.000 claims abstract 2
- 201000001421 hyperglycemia Diseases 0.000 claims abstract 2
- 235000020824 obesity Nutrition 0.000 claims abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 40
- 239000001257 hydrogen Substances 0.000 claims 40
- 125000003118 aryl group Chemical group 0.000 claims 39
- 150000002431 hydrogen Chemical class 0.000 claims 29
- 125000001072 heteroaryl group Chemical group 0.000 claims 27
- 125000000623 heterocyclic group Chemical group 0.000 claims 27
- 125000001188 haloalkyl group Chemical group 0.000 claims 21
- 229910052717 sulfur Inorganic materials 0.000 claims 20
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 16
- 229910052760 oxygen Inorganic materials 0.000 claims 15
- -1 cyano, hydroxyl Chemical group 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 13
- 150000002367 halogens Chemical class 0.000 claims 13
- 125000004104 aryloxy group Chemical group 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 12
- 125000004438 haloalkoxy group Chemical group 0.000 claims 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 9
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 7
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000005330 8 membered heterocyclic group Chemical group 0.000 claims 3
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 206010022489 Insulin Resistance Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 2
- 229910052794 bromium Inorganic materials 0.000 claims 2
- 125000004452 carbocyclyl group Chemical group 0.000 claims 2
- 150000003857 carboxamides Chemical class 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 208000000103 Anorexia Nervosa Diseases 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- 206010070901 Diabetic dyslipidaemia Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 229940122355 Insulin sensitizer Drugs 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 102000001494 Sterol O-Acyltransferase Human genes 0.000 claims 1
- 108010054082 Sterol O-acyltransferase Proteins 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000002404 acyltransferase inhibitor Substances 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 229910052727 yttrium Inorganic materials 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 0 *C(*N(*)S(*)(=O)=O)Sc(cc1)cc(*)c1OCC(O)=O Chemical compound *C(*N(*)S(*)(=O)=O)Sc(cc1)cc(*)c1OCC(O)=O 0.000 description 14
- NGAUPTCQRVRLGS-UHFFFAOYSA-N CC(C)(C)OC(CCc(c(CNC(c(cc([s]1)Cl)c1Cl)=O)c1)ccc1O)=O Chemical compound CC(C)(C)OC(CCc(c(CNC(c(cc([s]1)Cl)c1Cl)=O)c1)ccc1O)=O NGAUPTCQRVRLGS-UHFFFAOYSA-N 0.000 description 1
- WHWQIMVZDAQUGD-UHFFFAOYSA-N CC(C)(C)OC(COc(c(C)c1)c(C)cc1O)=O Chemical compound CC(C)(C)OC(COc(c(C)c1)c(C)cc1O)=O WHWQIMVZDAQUGD-UHFFFAOYSA-N 0.000 description 1
- SFMXWVFJRXAWHL-UHFFFAOYSA-N CCC(CN1Cc(cc2)ccc2OC)OS1(=O)=O Chemical compound CCC(CN1Cc(cc2)ccc2OC)OS1(=O)=O SFMXWVFJRXAWHL-UHFFFAOYSA-N 0.000 description 1
- YICLNBQQJHTOIA-UHFFFAOYSA-N CCC(CN1Cc(cc2)ccc2OC)OS1=O Chemical compound CCC(CN1Cc(cc2)ccc2OC)OS1=O YICLNBQQJHTOIA-UHFFFAOYSA-N 0.000 description 1
- RSQFBBSWBKFCGN-HQBPLYTQSA-N CCC(CNC/C(/C=C\C(C)(C)OC)=C/C)O Chemical compound CCC(CNC/C(/C=C\C(C)(C)OC)=C/C)O RSQFBBSWBKFCGN-HQBPLYTQSA-N 0.000 description 1
- OTUNUYALXOCROJ-UHFFFAOYSA-N CCC(CNCc(cc1)ccc1OC)O Chemical compound CCC(CNCc(cc1)ccc1OC)O OTUNUYALXOCROJ-UHFFFAOYSA-N 0.000 description 1
- BBGWPCQSHXNFLR-UHFFFAOYSA-N CCCN(CC(C)O)S(c1c(C)c2cc(F)ccc2[s]1)(=O)=O Chemical compound CCCN(CC(C)O)S(c1c(C)c2cc(F)ccc2[s]1)(=O)=O BBGWPCQSHXNFLR-UHFFFAOYSA-N 0.000 description 1
- HMACHCIMSLCIFL-UHFFFAOYSA-O CCCN(CC(C)O[SH+](C)(C)C(C)(C)C)S(c1c(C(F)(F)F)c2cc(Cl)ccc2[s]1)(=O)=O Chemical compound CCCN(CC(C)O[SH+](C)(C)C(C)(C)C)S(c1c(C(F)(F)F)c2cc(Cl)ccc2[s]1)(=O)=O HMACHCIMSLCIFL-UHFFFAOYSA-O 0.000 description 1
- ANFCXVZNJKOONK-UHFFFAOYSA-N CCCN(CC(CC)OC1=CCC(CCC(O)=[O-])C(C)=C1)S(c1c(C)c2cc(Cl)ccc2[s]1)(=O)=O Chemical compound CCCN(CC(CC)OC1=CCC(CCC(O)=[O-])C(C)=C1)S(c1c(C)c2cc(Cl)ccc2[s]1)(=O)=O ANFCXVZNJKOONK-UHFFFAOYSA-N 0.000 description 1
- JCPRAZQPQKHTHX-UHFFFAOYSA-N CCCN(CC(CC)Sc(cc1)cc(C)c1OCC(OCC)=O)S(c1c(C)c2cc(Cl)ccc2[s]1)(=O)=O Chemical compound CCCN(CC(CC)Sc(cc1)cc(C)c1OCC(OCC)=O)S(c1c(C)c2cc(Cl)ccc2[s]1)(=O)=O JCPRAZQPQKHTHX-UHFFFAOYSA-N 0.000 description 1
- OPNDSKNSNMUDGX-UHFFFAOYSA-N CCCN(CCOS(c1ccc(C)cc1)(=O)=O)S(c1ccccc1)(=O)=O Chemical compound CCCN(CCOS(c1ccc(C)cc1)(=O)=O)S(c1ccccc1)(=O)=O OPNDSKNSNMUDGX-UHFFFAOYSA-N 0.000 description 1
- BOBDYEASWNMGBA-UHFFFAOYSA-N CCCN(CCOc1ccc2[n](C(C)(C)C(O)=O)ccc2c1)S(c1c(C)c2cc(F)ccc2[s]1)(=O)=O Chemical compound CCCN(CCOc1ccc2[n](C(C)(C)C(O)=O)ccc2c1)S(c1c(C)c2cc(F)ccc2[s]1)(=O)=O BOBDYEASWNMGBA-UHFFFAOYSA-N 0.000 description 1
- MVVPUSMJRNRJDV-UHFFFAOYSA-O CCCN(CCOc1ccc2[n](C(C)(C)C(O)=O)ccc2c1)[SH+](c1c(C)c2cc(Cl)ccc2[s]1)=O Chemical compound CCCN(CCOc1ccc2[n](C(C)(C)C(O)=O)ccc2c1)[SH+](c1c(C)c2cc(Cl)ccc2[s]1)=O MVVPUSMJRNRJDV-UHFFFAOYSA-O 0.000 description 1
- SWCVOEDLQCWDHU-UHFFFAOYSA-N CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c(cc1)ccc1Cl)(=O)=O Chemical compound CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c(cc1)ccc1Cl)(=O)=O SWCVOEDLQCWDHU-UHFFFAOYSA-N 0.000 description 1
- ZMGUCNXJJAIPSF-UHFFFAOYSA-N CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c(ccc(Cl)c1)c1Cl)(=O)=O Chemical compound CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c(ccc(Cl)c1)c1Cl)(=O)=O ZMGUCNXJJAIPSF-UHFFFAOYSA-N 0.000 description 1
- YKVYHAGMKMICCF-UHFFFAOYSA-N CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c1c(C(F)(F)F)c(cc(cc2)Cl)c2[s]1)=O Chemical compound CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c1c(C(F)(F)F)c(cc(cc2)Cl)c2[s]1)=O YKVYHAGMKMICCF-UHFFFAOYSA-N 0.000 description 1
- VOVZPBZMENGRMJ-UHFFFAOYSA-N CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c1cc(-c(cc2)cnc2OC)ccc1)(=O)=O Chemical compound CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c1cc(-c(cc2)cnc2OC)ccc1)(=O)=O VOVZPBZMENGRMJ-UHFFFAOYSA-N 0.000 description 1
- UYOPZDSQYYRXIQ-UHFFFAOYSA-N CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c1ccccc1)(=O)=O Chemical compound CCCN(CCSc(cc1)cc(C)c1OCC(O)=O)S(c1ccccc1)(=O)=O UYOPZDSQYYRXIQ-UHFFFAOYSA-N 0.000 description 1
- DHEYGFPRRYHENU-UHFFFAOYSA-N CCCN(CCSc(cc1)cc(Cl)c1OCC(O)=O)S(c1c(C)c(cc(cc2)Cl)c2[s]1)(=O)=O Chemical compound CCCN(CCSc(cc1)cc(Cl)c1OCC(O)=O)S(c1c(C)c(cc(cc2)Cl)c2[s]1)(=O)=O DHEYGFPRRYHENU-UHFFFAOYSA-N 0.000 description 1
- XPDILMCIGFGBBJ-UHFFFAOYSA-N CCCN(CCSc(cc1)ccc1OCC(O)=O)S(c1c(C)c(cc(cc2)Cl)c2[s]1)(=O)=O Chemical compound CCCN(CCSc(cc1)ccc1OCC(O)=O)S(c1c(C)c(cc(cc2)Cl)c2[s]1)(=O)=O XPDILMCIGFGBBJ-UHFFFAOYSA-N 0.000 description 1
- YCPIZBGVYGZOCZ-UHFFFAOYSA-N CCCN(CCSc(cc1C)ccc1OCC(O)=O)S(c(cc1)ccc1C1=CC(F)=CCC1)(=O)=O Chemical compound CCCN(CCSc(cc1C)ccc1OCC(O)=O)S(c(cc1)ccc1C1=CC(F)=CCC1)(=O)=O YCPIZBGVYGZOCZ-UHFFFAOYSA-N 0.000 description 1
- IULYUGJAPIYEDC-UHFFFAOYSA-N CCCN(CCSc(cc1C)ccc1OCC(O)=O)S(c1ccc(CC)cc1)(=O)=O Chemical compound CCCN(CCSc(cc1C)ccc1OCC(O)=O)S(c1ccc(CC)cc1)(=O)=O IULYUGJAPIYEDC-UHFFFAOYSA-N 0.000 description 1
- HEAIQPMBSSANBJ-UHFFFAOYSA-N CCCN(CCSc(cc1C)ccc1O[IH]C(O)=O)S(c(c1ccc2)cccc1c2Cl)(=O)=O Chemical compound CCCN(CCSc(cc1C)ccc1O[IH]C(O)=O)S(c(c1ccc2)cccc1c2Cl)(=O)=O HEAIQPMBSSANBJ-UHFFFAOYSA-N 0.000 description 1
- WOBIFTXCETXCFI-MRXNPFEDSA-N CCCN(C[C@@H](C)Sc(cc1)cc(C)c1OCC(O)=O)S(c1c(C)c2cc(Cl)ccc2[s]1)(=O)=O Chemical compound CCCN(C[C@@H](C)Sc(cc1)cc(C)c1OCC(O)=O)S(c1c(C)c2cc(Cl)ccc2[s]1)(=O)=O WOBIFTXCETXCFI-MRXNPFEDSA-N 0.000 description 1
- XXWAMYMUKLOACY-LJQANCHMSA-N CCCN(C[C@@H](C)Sc(cc1C)ccc1OCC(OCC)=O)[Si](C1=CCCC=C1)=O Chemical compound CCCN(C[C@@H](C)Sc(cc1C)ccc1OCC(OCC)=O)[Si](C1=CCCC=C1)=O XXWAMYMUKLOACY-LJQANCHMSA-N 0.000 description 1
- WPVVWLXGHXMNMA-UHFFFAOYSA-N CCCNS(c(cc1)ccc1[N+]([O-])=O)(=O)=O Chemical compound CCCNS(c(cc1)ccc1[N+]([O-])=O)(=O)=O WPVVWLXGHXMNMA-UHFFFAOYSA-N 0.000 description 1
- RKPCGHDWKDURPX-UHFFFAOYSA-N CCCNS(c(cccc1)c1OC(F)(F)F)(O)=O Chemical compound CCCNS(c(cccc1)c1OC(F)(F)F)(O)=O RKPCGHDWKDURPX-UHFFFAOYSA-N 0.000 description 1
- FGPQIGWVAVAJNC-UHFFFAOYSA-N CCCNS(c1ccc(C=CCC2)c2c1)=O Chemical compound CCCNS(c1ccc(C=CCC2)c2c1)=O FGPQIGWVAVAJNC-UHFFFAOYSA-N 0.000 description 1
- QOKOQKAUSWFFCM-UHFFFAOYSA-N CCCc(cc(cc1)OCCBr)c1OC(C)(C)C(OCC)=O Chemical compound CCCc(cc(cc1)OCCBr)c1OC(C)(C)C(OCC)=O QOKOQKAUSWFFCM-UHFFFAOYSA-N 0.000 description 1
- BNOITVNUPDVDRH-UHFFFAOYSA-N CCOC(C(C)[n](cc1)c(cc2)c1cc2C#CCO)=O Chemical compound CCOC(C(C)[n](cc1)c(cc2)c1cc2C#CCO)=O BNOITVNUPDVDRH-UHFFFAOYSA-N 0.000 description 1
- AUDUKCBPTKCPCT-UHFFFAOYSA-N CCOC(c1c(C)c(ccc(Cl)c2)c2[s]1)=O Chemical compound CCOC(c1c(C)c(ccc(Cl)c2)c2[s]1)=O AUDUKCBPTKCPCT-UHFFFAOYSA-N 0.000 description 1
- BVAOMUZNANWAIH-IBGZPJMESA-N CCc1cc(SC[C@H](CCC2)N2S(c2c(C)c3cc(C)ccc3[s]2)(=O)=O)ccc1OCC(O)=O Chemical compound CCc1cc(SC[C@H](CCC2)N2S(c2c(C)c3cc(C)ccc3[s]2)(=O)=O)ccc1OCC(O)=O BVAOMUZNANWAIH-IBGZPJMESA-N 0.000 description 1
- GYECROLIZPLTMN-UHFFFAOYSA-N CN(C(c(ccc(Cl)c1)c1F)=O)OC Chemical compound CN(C(c(ccc(Cl)c1)c1F)=O)OC GYECROLIZPLTMN-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/17—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/46—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms
- C07C323/49—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/12—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
- C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
- C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/30—Hetero atoms other than halogen
- C07D333/34—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Lubricants (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44830703P | 2003-02-14 | 2003-02-14 | |
| US448307P | 2003-02-14 | ||
| PCT/US2004/002015 WO2004073606A2 (en) | 2003-02-14 | 2004-02-10 | Sulfonamide derivatives as ppar modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004010889D1 DE602004010889D1 (de) | 2008-02-07 |
| DE602004010889T2 true DE602004010889T2 (de) | 2008-12-11 |
Family
ID=32908574
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004010889T Expired - Fee Related DE602004010889T2 (de) | 2003-02-14 | 2004-02-10 | Sulfonamid-derivate als ppar-modulatoren |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7655641B2 (enExample) |
| EP (1) | EP1597248B1 (enExample) |
| JP (1) | JP2006520755A (enExample) |
| CN (1) | CN1751037A (enExample) |
| AT (1) | ATE382043T1 (enExample) |
| AU (1) | AU2004212887A1 (enExample) |
| BR (1) | BRPI0407180A (enExample) |
| CA (1) | CA2512883A1 (enExample) |
| DE (1) | DE602004010889T2 (enExample) |
| ES (1) | ES2297382T3 (enExample) |
| MX (1) | MXPA05008581A (enExample) |
| WO (1) | WO2004073606A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7517884B2 (en) | 1998-03-30 | 2009-04-14 | Kalypsys Inc. | Sulfonyl-substituted bicyclic compounds as modulators of PPAR |
| KR100761615B1 (ko) | 2003-11-05 | 2007-10-04 | 에프. 호프만-라 로슈 아게 | Ppar 활성화제로서 헤테로아릴 유도체 |
| EP1745014B1 (en) | 2004-05-05 | 2011-07-06 | High Point Pharmaceuticals, LLC | Novel compounds, their preparation and use |
| WO2005105726A1 (en) | 2004-05-05 | 2005-11-10 | Novo Nordisk A/S | Novel compounds, their preparation and use |
| BRPI0516435B1 (pt) | 2004-10-29 | 2021-09-21 | Kalypsys , Inc | Composto, e composição farmacêutica |
| WO2007005455A2 (en) * | 2005-06-30 | 2007-01-11 | Bayer Cropscience Ag | Improved process for preparing (disubstitutedpropenyl) phenylalkyl substituted heterocycles |
| US7943669B2 (en) | 2005-06-30 | 2011-05-17 | High Point Pharmaceuticals, Llc | Phenoxy acetic acids as PPAR delta activators |
| US7915316B2 (en) * | 2005-08-22 | 2011-03-29 | Allergan, Inc | Sulfonamides |
| EP1939175B1 (en) * | 2005-09-27 | 2017-03-01 | Shionogi&Co., Ltd. | Sulfonamide derivative having pgd2 receptor antagonistic activity |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| AU2006305769B2 (en) | 2005-10-25 | 2012-06-14 | Kalypsys, Inc. | Salts of modulators of PPAR and methods of treating metabolic disorders |
| US7943613B2 (en) | 2005-12-22 | 2011-05-17 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
| CA2645719A1 (en) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Compounds that modulate ppar activity, their preparation and use |
| JP5189345B2 (ja) * | 2006-11-06 | 2013-04-24 | 東ソー株式会社 | トリフルオロメチル化用反応試剤 |
| US20080176861A1 (en) | 2007-01-23 | 2008-07-24 | Kalypsys, Inc. | Sulfonyl-substituted bicyclic compounds as ppar modulators for the treatment of non-alcoholic steatohepatitis |
| KR101152659B1 (ko) * | 2009-10-09 | 2012-06-15 | 한국과학기술연구원 | 세로토닌 수용체 길항 작용과 세로토닌 트랜스포터 억제 작용을 동시에 가지는 설폰아마이드 화합물 |
| CA2809958A1 (en) | 2010-08-31 | 2012-03-08 | Snu R & Db Foundation | Use of the fetal reprogramming of a ppar ? agonist |
| JP5767458B2 (ja) * | 2010-11-09 | 2015-08-19 | スガイ化学工業株式会社 | ポリオキシエチレン付加カリックスアレーン誘導体の製造方法 |
| CN102336689A (zh) * | 2011-08-29 | 2012-02-01 | 天津市筠凯化工科技有限公司 | 4-氯-3-(三氟甲基)苯磺酰氯的制备及其精制方法 |
| KR20140099546A (ko) | 2012-01-10 | 2014-08-12 | 일라이 릴리 앤드 캄파니 | 류코트리엔 b4 길항제 화합물 |
| ES2811087T3 (es) | 2013-09-09 | 2021-03-10 | Vtv Therapeutics Llc | Uso de agonistas de PPAR-delta para tratar la atrofia muscular |
| WO2016057322A1 (en) | 2014-10-08 | 2016-04-14 | Salk Institute For Biological Studies | Ppar agonists and methods of use thereof |
| US10188627B2 (en) | 2014-10-08 | 2019-01-29 | Mitobridge, Inc. | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof |
| US10103402B2 (en) * | 2015-12-01 | 2018-10-16 | University Of Kentucky Research Foundation | Liquid phenothiazine catholytes for non-aqueous redox flow batteries |
| WO2023147309A1 (en) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Use of ppar-delta agonists in the treatment of disease |
| CN119405633B (zh) * | 2024-11-25 | 2025-12-02 | 浙江大学 | 2,6-dmhq在抗心脏和肝脏缺血再灌注损伤中的应用 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084466A (en) * | 1989-01-31 | 1992-01-28 | Hoffmann-La Roche Inc. | Novel carboxamide pyridine compounds which have useful pharmaceutical utility |
| US5089514A (en) | 1990-06-14 | 1992-02-18 | Pfizer Inc. | 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents |
| JPH05125038A (ja) * | 1991-03-07 | 1993-05-21 | Tanabe Seiyaku Co Ltd | フエノキシアルカン酸誘導体及びその製法 |
| JPH05194370A (ja) * | 1992-01-22 | 1993-08-03 | Taisho Pharmaceut Co Ltd | スルホンアミド誘導体 |
| US5232945A (en) | 1992-07-20 | 1993-08-03 | Pfizer Inc. | 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives |
| JPH0672867A (ja) * | 1992-08-27 | 1994-03-15 | Tanabe Seiyaku Co Ltd | 抗脂血剤 |
| US5902726A (en) | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
| US6062509A (en) | 1994-12-23 | 2000-05-16 | Hexcel Corporation | Retrofit centerline luggage bin assemblies compatible with existing aircraft bin supports |
| WO1996025926A1 (en) * | 1995-02-21 | 1996-08-29 | Nippon Suisan Kaisha, Ltd. | Glutamic acid receptor agonist |
| WO1997028115A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Antidiabetic agents |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| US6200995B1 (en) * | 1998-01-29 | 2001-03-13 | Tularik Inc. | PPAR-γ modulators |
| KR100620337B1 (ko) | 1998-03-10 | 2006-09-13 | 오노 야꾸힝 고교 가부시키가이샤 | 카르복실산 유도체와 그 유도체를 유효 성분으로서함유하는 약제 |
| GB9822473D0 (en) * | 1998-10-16 | 1998-12-09 | Glaxo Group Ltd | Chemical compounds |
| US6248781B1 (en) | 1998-10-21 | 2001-06-19 | Novo Nordisk A/S | Compounds useful in the treatment of conditions mediated by peroxisome proliferator-activated receptors (PPAR) |
| RU2219172C2 (ru) | 1999-04-06 | 2003-12-20 | Санкио Компани, Лимитед | α-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ КАРБОНОВЫХ КИСЛОТ |
| PT1177187E (pt) * | 1999-04-28 | 2007-09-03 | Sanofi Aventis Deutschland | Derivados ácidos de di-arilo como ligados do receptor ppar. |
| AU5886900A (en) | 1999-06-25 | 2001-01-31 | Institutes For Pharmaceutical Discovery, Llc, The | Substituted phenoxyacetic acids |
| AU7073400A (en) | 1999-08-27 | 2001-03-26 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| TWI262185B (en) | 1999-10-01 | 2006-09-21 | Eisai Co Ltd | Carboxylic acid derivatives having anti-hyperglycemia and anti-hyperlipemia action, and pharmaceutical composition containing the derivatives |
| AU7995300A (en) * | 1999-10-05 | 2001-05-10 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| PE20011010A1 (es) * | 1999-12-02 | 2001-10-18 | Glaxo Group Ltd | Oxazoles y tiazoles sustituidos como agonista del receptor activado por el proliferador de peroxisomas humano |
| JP4316787B2 (ja) | 2000-01-11 | 2009-08-19 | 壽製薬株式会社 | エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、 |
| US7176224B2 (en) | 2000-08-23 | 2007-02-13 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as PPAR agonists |
| CA2420178A1 (en) | 2000-08-23 | 2002-03-07 | Eli Lilly And Company | Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| US7071220B2 (en) * | 2000-09-18 | 2006-07-04 | Toa Eiyo Ltd. | N-substituted benzothiophenesulfonamide derivatives |
| US6852738B2 (en) * | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| EP1372632A1 (en) * | 2001-02-15 | 2004-01-02 | Pfizer Products Inc. | Proliferative activator receptor (ppar) compounds |
| IL158873A0 (en) | 2001-06-07 | 2004-05-12 | Lilly Co Eli | Modulators of peroxisome proliferator activated receptors |
| ATE375350T1 (de) * | 2002-02-21 | 2007-10-15 | Lilly Co Eli | Modulatoren von peroxisome proliferator- aktivierten rezeptoren |
-
2004
- 2004-02-10 BR BR0407180-8A patent/BRPI0407180A/pt not_active Application Discontinuation
- 2004-02-10 JP JP2006502992A patent/JP2006520755A/ja active Pending
- 2004-02-10 MX MXPA05008581A patent/MXPA05008581A/es active IP Right Grant
- 2004-02-10 CN CNA2004800042507A patent/CN1751037A/zh active Pending
- 2004-02-10 CA CA002512883A patent/CA2512883A1/en not_active Abandoned
- 2004-02-10 AU AU2004212887A patent/AU2004212887A1/en not_active Abandoned
- 2004-02-10 ES ES04709806T patent/ES2297382T3/es not_active Expired - Lifetime
- 2004-02-10 DE DE602004010889T patent/DE602004010889T2/de not_active Expired - Fee Related
- 2004-02-10 EP EP04709806A patent/EP1597248B1/en not_active Expired - Lifetime
- 2004-02-10 WO PCT/US2004/002015 patent/WO2004073606A2/en not_active Ceased
- 2004-02-10 US US10/542,579 patent/US7655641B2/en not_active Expired - Fee Related
- 2004-02-10 AT AT04709806T patent/ATE382043T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1751037A (zh) | 2006-03-22 |
| EP1597248B1 (en) | 2007-12-26 |
| MXPA05008581A (es) | 2005-11-04 |
| WO2004073606A3 (en) | 2005-03-31 |
| CA2512883A1 (en) | 2004-09-02 |
| JP2006520755A (ja) | 2006-09-14 |
| US7655641B2 (en) | 2010-02-02 |
| US20060217433A1 (en) | 2006-09-28 |
| WO2004073606A2 (en) | 2004-09-02 |
| ES2297382T3 (es) | 2008-05-01 |
| DE602004010889D1 (de) | 2008-02-07 |
| BRPI0407180A (pt) | 2006-02-07 |
| ATE382043T1 (de) | 2008-01-15 |
| AU2004212887A1 (en) | 2004-09-02 |
| EP1597248A2 (en) | 2005-11-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004010889T2 (de) | Sulfonamid-derivate als ppar-modulatoren | |
| DE60216094T2 (de) | Modulatoren der peroxisom-proliferator-aktivierten rezeptoren (ppar) | |
| DE602004011985T2 (de) | Modulatoren des peroxisomproliferatoraktivierten rezeptors | |
| DE69403823T2 (de) | Substituierte Phenylsulfonamine als selektive B3-Agonisten zur Behandlung von Diabetes und Fettleibigkeit | |
| JP6095580B2 (ja) | 芳香環化合物 | |
| KR100196356B1 (ko) | 당뇨병 치료제 | |
| DE69418311T2 (de) | Isoxazolidindionderivate und deren verwendung | |
| CN105209448B (zh) | 三环化合物及其用途 | |
| US20080312237A1 (en) | Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same | |
| KR19990087321A (ko) | Ppar-감마에 대한 효능제 활성을 갖는 치환된 4-히드록시-페닐알카논산 유도체 | |
| WO2013122029A1 (ja) | 芳香環化合物 | |
| UA76773C2 (uk) | Діарилциклоалкільні похідні, спосіб їх одержання і їх застосування як ppar-активаторів | |
| JP2015506349A (ja) | 非全身性tgr5アゴニスト | |
| TW200918053A (en) | Heteroaryl benzene compound | |
| JP2002526442A (ja) | プロスタグランジンe2アンタゴニストの新規用途 | |
| DE60128239T2 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
| JPWO2002046176A1 (ja) | ペルオキシソーム増殖剤応答性受容体の活性化剤 | |
| CZ2004272A3 (cs) | Perorální antidiabetická činidla | |
| JP2007508382A (ja) | Pparモジュレータとしてのフェノキシエーテル誘導体 | |
| WO1994001433A1 (fr) | Nouveau compose de thiazolidinedione et son utilisation | |
| DE60131001T2 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
| WO2018140338A1 (en) | Amide compounds and use thereof | |
| JP2000344748A (ja) | 3−芳香族置換プロピオン酸またはアクリル酸化合物 | |
| JPH0546335B2 (enExample) | ||
| JPWO2012081570A1 (ja) | ラクタム化合物又はその塩及びppar活性化剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336 |
|
| R119 | Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee |
Ref document number: 1597248 Country of ref document: EP Effective date: 20110901 |
|
| R082 | Change of representative |
Ref document number: 1597248 Country of ref document: EP Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN, DE |